CIZZLE BIOTECHNOLOGY HOLDINGS PLC Logo

CIZZLE BIOTECHNOLOGY HOLDINGS PLC

Developing a CIZ1B biomarker blood test for the early detection of lung cancer.

CIZ | IL

Overview

Corporate Details

ISIN(s):
GB00BNG2VN02
LEI:
213800G3OS3SA2J1Y358
Country:
United Kingdom
Address:
6TH FLOOR, 60 GRACECHURCH STREET, EC3V 0HR LONDON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Cizzle Biotechnology Holdings PLC is a diagnostics company developing a non-invasive blood test for the early detection of lung cancer. The company's core product utilizes its proprietary CIZ1B biomarker, an advanced immunoassay designed to identify lung cancer at its earliest, most treatable stages with high sensitivity. This cost-effective solution aims to streamline the diagnostic pathway for healthcare providers, reducing reliance on CT scans and minimizing unnecessary invasive follow-up procedures. Originating as a spin-out from the University of York, Cizzle is advancing its technology through global clinical trials to secure regulatory approval and improve patient outcomes worldwide.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 08:35
Capital/Financing Update
£250,000 Convertible Loan Note Issue
English 16.3 KB
2025-11-05 08:20
Regulatory News Service
LOI with leading UK Clinical Diagnostic Group
English 16.3 KB
2025-09-29 08:00
Regulatory News Service
Update on Clinical Laboratory Partnerships in USA
English 22.2 KB
2025-08-18 08:00
Regulatory News Service
Commercial Progress in USA
English 22.0 KB
2025-07-08 10:40
Annual Report
Annual Report for the year ended 31 December 2024
English 332.7 KB
2025-06-06 12:00
Report Publication Announcement
Notice of AGM
English 11.4 KB
2025-05-28 08:00
Major Shareholding Notification
Holding(s) in Company
English 51.1 KB
2025-03-25 08:00
Board/Management Information
Appointment of Non-Executive Director
English 15.7 KB
2025-01-02 08:00
Board/Management Information
Appointment of Professor Dawn Coverley as CSO
English 17.8 KB
2024-12-16 08:00
M&A Activity
Update on Strategic Partnership in North America
English 23.8 KB
2024-10-21 08:00
M&A Activity
Execution of Agreement for North America
English 25.9 KB
2024-10-03 14:12
Regulatory News Service
Update on Licensing and Partnership Agreement
English 10.6 KB
2024-09-30 08:00
Interim Report
Interim Results
English 208.3 KB
2024-09-16 08:00
Major Shareholding Notification
Holding(s) in Company
English 37.5 KB
2024-09-09 08:00
Regulatory News Service
Collaboration with Moffitt Cancer Center
English 25.0 KB

Automate Your Workflow. Get a real-time feed of all CIZZLE BIOTECHNOLOGY HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CIZZLE BIOTECHNOLOGY HOLDINGS PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CIZZLE BIOTECHNOLOGY HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.